{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T09:09:41Z","timestamp":1789204181362,"version":"build-2803163510"},"reference-count":44,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T00:00:00Z","timestamp":1700697600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002855","name":"Ministry of Science and Technology of the People's Republic of China","doi-asserted-by":"publisher","award":["2018ZX09711001-004-006"],"award-info":[{"award-number":["2018ZX09711001-004-006"]}],"id":[{"id":"10.13039\/501100002855","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012245","name":"Science and Technology Planning Project of Guangdong Province","doi-asserted-by":"publisher","award":["2018B030334001"],"award-info":[{"award-number":["2018B030334001"]}],"id":[{"id":"10.13039\/501100012245","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.apsb.2023.11.024","type":"journal-article","created":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T12:10:51Z","timestamp":1700827851000},"page":"1457-1466","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["A novel dual serotonin transporter and M-channel inhibitor D01 for antidepression and cognitive improvement"],"prefix":"10.1016","volume":"14","author":[{"given":"Yaqin","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangqing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinli","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5038-6218","authenticated-orcid":false,"given":"Dongli","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenwen","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yani","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7023-9998","authenticated-orcid":false,"given":"KeWei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2023.11.024_bib1","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1124\/jpet.118.248351","article-title":"Pharmacological characterization of H05, a novel serotonin and noradrenaline reuptake inhibitor with moderate 5-HT2A antagonist activity for the treatment of depression","volume":"365","author":"Xu","year":"2018","journal-title":"J Pharmacol Exp Therapeut"},{"key":"10.1016\/j.apsb.2023.11.024_bib2","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1007\/s12035-015-9152-z","article-title":"Revisiting the serotonin hypothesis: implications for major depressive disorders","volume":"53","author":"Fakhoury","year":"2016","journal-title":"Mol Neurobiol"},{"key":"10.1016\/j.apsb.2023.11.024_bib3","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/JCP.0b013e31820ebd2c","article-title":"Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication","volume":"31","author":"McClintock","year":"2011","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.apsb.2023.11.024_bib4","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s44220-023-00033-z","article-title":"Major depression, physical health and molecular senescence markers abnormalities","volume":"1","author":"Seitz-Holland","year":"2023","journal-title":"Nat Mental Health"},{"key":"10.1016\/j.apsb.2023.11.024_bib5","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.jad.2023.02.133","article-title":"The percentage of cognitive impairment in patients with major depressive disorder over the course of the depression: a longitudinal study","volume":"329","author":"Liu","year":"2023","journal-title":"J Affect Disord"},{"key":"10.1016\/j.apsb.2023.11.024_bib6","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jad.2019.08.091","article-title":"Influence of comorbid anxiety symptoms on cognitive deficits in patients with major depressive disorder","volume":"260","author":"Liu","year":"2020","journal-title":"J Affect Disord"},{"key":"10.1016\/j.apsb.2023.11.024_bib7","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/nrd3628","article-title":"Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy","volume":"11","author":"Millan","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2023.11.024_bib8","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1017\/S003329170800411X","article-title":"Cognitive impairment in unipolar depression is persistent and non-specific: further evidence for the final common pathway disorder hypothesis","volume":"39","author":"Reppermund","year":"2009","journal-title":"Psychol Med"},{"key":"10.1016\/j.apsb.2023.11.024_bib9","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12916-016-0560-3","article-title":"Cognitive remission: a novel objective for the treatment of major depression?","volume":"14","author":"Bortolato","year":"2016","journal-title":"BMC Med"},{"key":"10.1016\/j.apsb.2023.11.024_bib10","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1177\/0706743716659417","article-title":"Canadian network for mood and anxiety treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 3. Pharmacological treatments","volume":"61","author":"Kennedy","year":"2016","journal-title":"Can J Psychiatr"},{"key":"10.1016\/j.apsb.2023.11.024_bib11","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1017\/S1092852918001207","article-title":"Cognitive impairment in major depressive disorder","volume":"24","author":"Pan","year":"2019","journal-title":"CNS Spectr"},{"key":"10.1016\/j.apsb.2023.11.024_bib12","series-title":"Depressive cognitive disorders","author":"Sekhon","year":"2023"},{"key":"10.1016\/j.apsb.2023.11.024_bib13","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.2174\/1871527313666141130203627","article-title":"Cognitive dysfunction in depression\u2014pathophysiology and novel targets","volume":"13","author":"Carvalho","year":"2014","journal-title":"CNS Neurol Disord: Drug Targets"},{"key":"10.1016\/j.apsb.2023.11.024_bib14","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1007\/s00213-019-5175-x","article-title":"Targeting the immune system in the treatment of bipolar disorder","volume":"236","author":"Rosenblat","year":"2019","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.apsb.2023.11.024_bib15","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1017\/S1461145714000546","article-title":"A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults","volume":"17","author":"McIntyre","year":"2014","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.apsb.2023.11.024_bib16","doi-asserted-by":"crossref","first-page":"138","DOI":"10.4088\/JCP.08m04666yel","article-title":"A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia","volume":"71","author":"Levkovitz","year":"2010","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.apsb.2023.11.024_bib17","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.neulet.2012.01.051","article-title":"Evaluation of late cognitive impairment and anxiety states following traumatic brain injury in mice: the effect of minocycline","volume":"511","author":"Siopi","year":"2012","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.apsb.2023.11.024_bib18","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.cbi.2010.04.011","article-title":"N-Acetylcysteine prevents memory deficits, the decrease in acetylcholinesterase activity and oxidative stress in rats exposed to cadmium","volume":"186","author":"Goncalves","year":"2010","journal-title":"Chem Biol Interact"},{"key":"10.1016\/j.apsb.2023.11.024_bib19","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.neuroscience.2012.06.044","article-title":"N-Acetylcysteine reverses existing cognitive impairment and increased oxidative stress in glutamate transporter type 3 deficient mice","volume":"220","author":"Cao","year":"2012","journal-title":"Neuroscience"},{"key":"10.1016\/j.apsb.2023.11.024_bib20","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/j.jad.2011.04.059","article-title":"Effects of S-adenosylmethionine augmentation of serotonin-reuptake inhibitor antidepressants on cognitive symptoms of major depressive disorder","volume":"136","author":"Levkovitz","year":"2012","journal-title":"J Affect Disord"},{"key":"10.1016\/j.apsb.2023.11.024_bib21","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1038\/npp.2013.335","article-title":"Recombinant human erythropoietin for treating treatment-resistant depression: a double-blind, randomized, placebo-controlled phase 2 trial","volume":"39","author":"Miskowiak","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.apsb.2023.11.024_bib22","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1007\/s40265-016-0655-3","article-title":"Vortioxetine: a review in cognitive dysfunction in depression","volume":"76","author":"Frampton","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.apsb.2023.11.024_bib23","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s40263-014-0195-x","article-title":"Vortioxetine: a review of its use in major depressive disorder","volume":"28","author":"Garnock-Jones","year":"2014","journal-title":"CNS Drugs"},{"key":"10.1016\/j.apsb.2023.11.024_bib24","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1017\/S1092852913000540","article-title":"Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunction","volume":"19","author":"Pehrson","year":"2014","journal-title":"CNS Spectr"},{"key":"10.1016\/j.apsb.2023.11.024_bib25","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1111\/bph.14026","article-title":"Selective targeting of M-type potassium Kv 7.4 channels demonstrates their key role in the regulation of dopaminergic neuronal excitability and depression-like behaviour","volume":"174","author":"Li","year":"2017","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.apsb.2023.11.024_bib26","doi-asserted-by":"crossref","first-page":"5847","DOI":"10.1523\/JNEUROSCI.0348-20.2020","article-title":"In\u00a0vivo attenuation of M-current suppression impairs consolidation of object recognition memory","volume":"40","author":"Kosenko","year":"2020","journal-title":"J Neurosci"},{"key":"10.1016\/j.apsb.2023.11.024_bib27","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/283673a0","article-title":"Muscarinic suppression of a novel voltage-sensitive K+ current in a vertebrate neurone","volume":"283","author":"Brown","year":"1980","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2023.11.024_bib28","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1126\/science.282.5395.1890","article-title":"KCNQ2 and KCNQ3 potassium channel subunits: molecular correlates of the M-channel","volume":"282","author":"Wang","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.apsb.2023.11.024_bib29","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0091-3057(94)00368-S","article-title":"Linopiridine (DUP 996; AVIVA): its effects in the Morris water escape tank and on retention of an incompletely acquired bar-press response in rodents","volume":"51","author":"Flagmeyer","year":"1995","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.apsb.2023.11.024_bib30","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/hipo.20717","article-title":"The M-current inhibitor XE991 decreases the stimulation threshold for long-term synaptic plasticity in healthy mice and in models of cognitive disease","volume":"21","author":"Fontan-Lozano","year":"2011","journal-title":"Hippocampus"},{"key":"10.1016\/j.apsb.2023.11.024_bib31","doi-asserted-by":"crossref","first-page":"4720","DOI":"10.1111\/bph.15236","article-title":"Prefrontal inhibition of neuronal Kv 7 channels enhances prepulse inhibition of acoustic startle reflex and resistance to hypofrontality","volume":"177","author":"Wang","year":"2020","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.apsb.2023.11.024_bib32","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/164_2021_457","article-title":"Kv7 channels and excitability disorders","volume":"267","author":"Jones","year":"2021","journal-title":"Handb Exp Pharmacol"},{"issue":"Suppl 2","key":"10.1016\/j.apsb.2023.11.024_bib33","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/jnc.14052","article-title":"Cholinergic modulation of the hippocampal region and memory function","volume":"142","author":"Haam","year":"2017","journal-title":"J Neurochem"},{"key":"10.1016\/j.apsb.2023.11.024_bib34","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1016\/j.clinthera.2015.05.510","article-title":"Current practices in the treatment of alzheimer disease: where is the evidence after the phase III trials?","volume":"37","author":"Ehret","year":"2015","journal-title":"Clin Therapeut"},{"key":"10.1016\/j.apsb.2023.11.024_bib35","doi-asserted-by":"crossref","first-page":"9154","DOI":"10.1096\/fj.201802848RR","article-title":"Electrophysiological and pharmacological characterization of a novel and potent neuronal Kv7 channel opener SCR2682 for antiepilepsy","volume":"33","author":"Zhang","year":"2019","journal-title":"FASEB J"},{"key":"10.1016\/j.apsb.2023.11.024_bib36","doi-asserted-by":"crossref","first-page":"5512","DOI":"10.1021\/jm0309349","article-title":"Syntheses and binding studies of new [(aryl)(aryloxy)methyl]piperidine derivatives and related compounds as potential antidepressant drugs with high affinity for serotonin (5-HT) and norepinephrine (NE) transporters","volume":"46","author":"Orjales","year":"2003","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2023.11.024_bib37","first-page":"327","article-title":"Behavioral despair in mice: a primary screening test for antidepressants","volume":"229","author":"Porsolt","year":"1977","journal-title":"Arch Int Pharmacodyn Ther"},{"key":"10.1016\/j.apsb.2023.11.024_bib38","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/BF00428203","article-title":"The tail suspension test: a new method for screening antidepressants in mice","volume":"85","author":"Steru","year":"1985","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.apsb.2023.11.024_bib39","first-page":"5.59.1","article-title":"Novel object recognition in the rat: a facile assay for cognitive function","volume":"49","author":"Mathiasen","year":"2010","journal-title":"Curr Protoc Pharmacol"},{"key":"10.1016\/j.apsb.2023.11.024_bib40","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.bbr.2014.03.047","article-title":"Cotinine reduces depressive-like behavior, working memory deficits, and synaptic loss associated with chronic stress in mice","volume":"268","author":"Grizzell","year":"2014","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.apsb.2023.11.024_bib41","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1111\/j.1476-5381.2009.00111.x","article-title":"Neural KCNQ (Kv7) channels","volume":"156","author":"Brown","year":"2009","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.apsb.2023.11.024_bib42","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/epi.16494","article-title":"A knock-in mouse model for KCNQ2-related epileptic encephalopathy displays spontaneous generalized seizures and cognitive impairment","volume":"61","author":"Milh","year":"2020","journal-title":"Epilepsia"},{"key":"10.1016\/j.apsb.2023.11.024_bib43","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s10339-011-0430-z","article-title":"The novel object recognition memory: neurobiology, test procedure, and its modifications","volume":"13","author":"Antunes","year":"2012","journal-title":"Cognit Process"},{"key":"10.1016\/j.apsb.2023.11.024_bib44","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1152\/physrev.00014.2003","article-title":"Long-term potentiation and memory","volume":"84","author":"Lynch","year":"2004","journal-title":"Physiol Rev"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383523004471?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383523004471?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T17:05:24Z","timestamp":1761930324000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383523004471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S2211383523004471"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2023.11.024","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel dual serotonin transporter and M-channel inhibitor D01 for antidepression and cognitive improvement","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2023.11.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V. on behalf of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.","name":"copyright","label":"Copyright"}]}}